By Niranjan Gidwani, Certified Board Director (MCA – India) | ESG Director | Digital Leadership | UAE Superbrands Council Member
Category: Business
-
Artificial Intelligence and Startups: Shaping the Future with Innovation and Integrity
Data-led innovation drives these companies. Unlike traditional businesses that apply AI as a tool, AI-native startups incorporate it from inception. This design ensures rapid feedback loops, adaptive models, and an ability to serve niche markets, including Tier 2 and Tier 3 cities, with vernacular content and intelligent localization strategies based on regional languages.
India’s startup ecosystem has begun to embrace this model. According to various industry reports, more than 70 percent of Indian startups in 2025 are actively leveraging AI at core business levels. These include deploying predictive analytics for customer behavior, automating sales funnels, and improving operational cost efficiency by as much as 30 percent. As India develops its own foundational AI models tailored for its linguistic and cultural matrix, it opens the door for digital sovereignty and leadership in AI infrastructure.
As we step into the second half of the decade, the direction is clear: startups that treat AI not as a tactic, but as a foundational layer, will lead this transformation. These businesses will redefine how products are built, how teams collaborate, and how global markets are accessed. Success will come to those who build AI models that support, not replace, human intelligence.
-
NMDC Delivers Record June Production and Posts 31 Percent Growth in Q1 FY26
June output hits 3.57 million tonnes as quarterly volumes reach 11.99 million tonnes; new Dubai office signals entry into global minerals arena
NMDC Limited, the nation’s largest iron ore producer, announced record monthly output in June, reaching 3.57 million tonnes, the highest in its history, surpassing the 3.40 million tonnes produced in June 2024. June sales also set a new benchmark at 3.58 million tonnes.This milestone marked a strong start to fiscal year 2026. In the April–June quarter, NMDC produced 11.99 million tonnes of iron ore, reflecting a 31 percent increase over the 9.19 million tonnes delivered in Q1 FY25. Quarterly sales rose to 11.51 million tonnes, up 14 percent year-on-year, cementing it as the company’s best opening quarter yet.
Shri Amitava Mukherjee, Chairman and Managing Director of NMDC, attributed the performance to disciplined production processes, supply‑chain coordination, and value‑led execution. He emphasized the company’s readiness to sustain annual targets through operational resilience and innovation.
As part of its strategic expansion, NMDC inaugurated a new international office in Dubai, marking the first overseas corporate outpost in its 66-year history. The Dubai facility will serve as a springboard for broader market insights, enabling NMDC to track mineral demands in the Middle East, Africa, and Australia. This aligns with the company’s move toward diversification beyond iron ore to include strategic minerals such as copper, cobalt, and lithium.
The new office was unveiled in the presence of senior officials and dignitaries, including NMDC leadership and government representatives, signifying the company’s entry into the global minerals market with confidence and authority.
At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube. -
LT Foods Crosses USD 1 Billion Revenue Mark in FY’25, Reports 12 Percent Growth Year-on-Year
LT Foods crosses the USD 1 billion mark in FY’25 with robust growth across premium Basmati rice, organic foods, and ready-to-cook segments, underpinned by global distribution, product innovation, and digital transformation.
LT Foods Limited, a global player in the specialty rice and consumer food segment, has posted its consolidated audited financial results for the fiscal year ending 31 March 2025. The company recorded a total revenue of ₹8,770 crore, marking a 12 percent increase over the previous fiscal. The performance is driven by robust growth in its flagship basmati rice brand DAAWAT®, its expanding portfolio in organic ingredients, and the Ready-to-Heat and Ready-to-Cook segments.
The company’s gross profit rose to ₹3,030 crore in FY’25, reflecting a year-on-year increase of 19 percent. Gross margin expanded by 200 basis points to 34.5 percent. EBITDA stood at ₹1,067 crore, an 8 percent rise over FY’24, while net profit increased marginally to ₹612 crore. The earnings per share (EPS) improved slightly to ₹17.43 from ₹17.09 in the previous fiscal.
According to Mr. Ashwani Arora, Managing Director and Chief Executive Officer of LT Foods, the revenue milestone reflects consumer trust, innovation, and operational discipline across global markets. He stated that the company’s investments in its brand ecosystem, marketing, and distribution capabilities were instrumental in sustaining growth momentum. LT Foods’ India business saw continued investment in digital transformation and distribution strengthening, including the roll-out of its new go-to-market platform. Channels such as e-commerce and modern trade have contributed significantly to the company’s domestic footprint.The company’s international operations were key contributors. LT Foods distributes in over 80 countries and maintains a global footprint with supply chain hubs and manufacturing facilities in India, the United States, and Europe. Its North American rice brand Royal® continues to be a market leader, while its organic food division expanded by 29 percent in FY’25, reflecting rising demand for health-forward options.
Product innovation has been another pillar of growth. LT Foods launched several new items under its health and gourmet categories. These include DAAWAT® Jasmine Thai Rice and a gluten-free snack range under the brand Kari Kari, including the newly introduced Krispy Hopu with a sweet and salty flavour profile. The RTH and RTC portfolio, including variants such as Quick Cooking Black Rice, Red Rice, and Cuppa Rice, contributed ₹188 crore in revenue and saw 21 percent growth.The company’s performance is further underlined by financial stability. LT Foods maintained an interest coverage ratio of 10.0 and a net debt-to-equity ratio of 0.16 for FY’25. Its return on capital employed stood at 21 percent, and return on equity was recorded at 16.8 percent. Cash profit for the year reached ₹797 crore, up 6 percent from the previous year.
LT Foods, listed on the National Stock Exchange and BSE India, operates under an integrated farm-to-fork model. The company sources, processes, and distributes a portfolio of rice, organic food, and ingredients with certifications such as Kosher and Halal. The brand continues to align with sustainability goals, digital transformation, and responsible sourcing as part of its future strategy.DAAWAT®, its flagship brand, has remained one of India’s top-selling basmati labels. According to data from Wikipedia on Basmati rice, India accounts for more than 70 percent of global basmati exports, positioning LT Foods strategically in the global rice economy. The company’s focus on quality, traceability, and premiumization continues to drive its leadership in both the domestic and international food sectors.At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.
-
Hyderabad-based Brihaspathi Technologies Raises USD 10 Million, Secures MSRTC Project, and Announces IPO Plans
The company to deploy AI-powered security systems for MSRTC; prepares for IPO with a new 72,000 sq ft manufacturing unit and 400+ new hires planned
Brihaspathi Technologies Limited, a Hyderabad-headquartered leader in AI surveillance technology, has raised USD 10 million from foreign institutional investors to drive its next phase of growth. The funds will support a new 72,000 sq ft CCTV manufacturing facility in Hyderabad, expected to begin operations by March 2026.
The company plans to hire more than 400 staff across production, research, engineering and operations. It is preparing for an initial public offering during the 2026-27 fiscal year, with capital earmarked for R&D, factory expansion and AI innovation.
Brihaspathi has also secured a landmark contract to equip the Maharashtra State Road Transport Corporation with AI-enabled surveillance cameras and real-time monitoring systems. This public sector win reinforces Brihaspathi’s growing presence in national-scale infrastructure projects.To date, the firm has deployed over 1.2 million CCTV cameras across India. This includes surveillance for the Border Security Force, AI-based classroom monitoring systems, wildlife park deployments, and the deployment of 64,000 cameras in a single day across 19 states during the NEET examination.
The company expects approximately 30 percent year-on-year revenue growth in the current fiscal period. Its pan-India presence, with GST-enabled offices in 19 states and a young skilled workforce, positions it as one of the first Indian surveillance solution providers to draw foreign institutional investment.Rajasekhar Papolu, Managing Director of Brihaspathi Technologies, said this funding marks a transformational milestone. He highlighted that the new factory and the MSRTC surveillance project underscore Brihaspathi’s ability to deliver large-scale AI-driven security infrastructure. “As we get ready for our IPO next year, we remain focused on accelerating research innovation and enhancing manufacturing capacity,” he added.
With products that include AI-powered video analytics, solar surveillance cameras and smart city grade platforms, Brihaspathi is preparing to lead India’s homegrown surveillance revolution. The company’s official website provides detailed insights into its range of solutions and ongoing projects.At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.
-
Rubicon Research Limited Expands U.S. Specialty Footprint with Pithampur Unit Acquisition at ₹149 Crore
Rubicon Research strengthens its global presence by integrating a high potency manufacturing facility in Madhya Pradesh, further anchoring its commitment to regulated markets and innovation.
Rubicon Research Limited has acquired a formulations manufacturing unit from Alkem Laboratories in Pithampur, Madhya Pradesh, for ₹149 crore. This all-cash deal includes a fully operational site within the Indore Multi Product Special Economic Zone. The facility spans more than 125,000 square metres of land and includes over 16,000 square metres of built-up production space. It is currently licensed to manufacture complex and high-potency pharmaceuticals including oncology treatments, steroids, hormones, and immunosuppressants.
The site underwent a successful inspection by the United States Food and Drug Administration in 2022. With this acquisition, Rubicon now operates three manufacturing plants approved by the US FDA. The other two are located in Maharashtra. The company also runs advanced research and development centres in Thane and Concord, Ontario.Parag Sancheti, the Chief Executive Officer of Rubicon Research, stated that the Pithampur facility acquisition marks a key step in enhancing the company’s presence in regulated markets such as the United States. He added that the company plans to manufacture products for export through a supply chain that remains both agile and robust. This move also aligns with Rubicon’s strategy to broaden its portfolio of specialty and drug-device combination products. Under his leadership, the company continues to prioritise innovation and global expansion.
Alkem Laboratories, a pharmaceutical major headquartered in Mumbai since 1973, transferred this facility under a business arrangement signed in early January 2025. The transaction supports Alkem’s wider objective to streamline its production base and focus on core assets.Rubicon Research has delivered strong financial results over the past three years. Between the fiscal years 2022 and 2024, the company’s revenue rose from ₹313.6 crore to ₹853.9 crore. According to a report by Frost & Sullivan, this growth rate, over 62 percent annually, far outpaces the average seen among its Indian competitors. The company has a total of 69 active product approvals from the US FDA, including both ANDAs and NDAs. In fiscal 2024 alone, it received 14 new approvals. Rubicon is also one of the top-ranked Indian pharmaceutical companies in the specialty approvals segment between 2018 and 2023.
Investment in research and development remains one of Rubicon’s central priorities. In fiscal 2024, its research spending accounted for 13 percent of its total operating revenue. This level of investment is more than double the average seen across its peer group, again according to Frost & Sullivan data. The company is focused on building a portfolio that includes complex formulations, patent-protected delivery systems, and regulatory-first products.Pithampur is known for its industrial infrastructure and pharmaceutical exports. It is part of a growing economic corridor in central India, and its SEZ status provides Rubicon with several export-related benefits. According to official data, Pithampur and nearby Indore together recorded pharmaceutical exports worth over ₹14,000 crore in the previous financial year. The location offers access to logistics hubs, trained manpower, and manufacturing clusters.
Rubicon has also filed its Draft Red Herring Prospectus with the Securities and Exchange Board of India in July 2024, setting the stage for an initial public offering. The acquisition of this advanced manufacturing facility demonstrates Rubicon’s operational readiness and commitment to international compliance. With this new capacity, the company strengthens its ability to compete in markets where regulatory precision and manufacturing integrity are essential.At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.
-
Sigachi Industries Expands MCC Dominance and Launches API Manufacturing Facility in Andhra Pradesh
India’s top excipient player scales new verticals with the launch of a 25-acre API and specialty chemical site while maintaining its global MCC leadership.
Sigachi Industries Ltd., India’s largest manufacturer of Microcrystalline Cellulose (MCC), has announced the next phase of its expansion with the establishment of a bulk drugs and specialty chemicals facility in Orvakal, Andhra Pradesh. This vertically integrated move signals the company’s diversification into regulated Active Pharmaceutical Ingredients (APIs) and strengthens its capacity to serve global pharma and nutraceutical clients.
Sigachi has received Terms of Reference (ToR) approval from SEIAA, Andhra Pradesh, and will initiate its Environment Clearance (EC) process from July 15, 2025. Development is scheduled to begin on August 1, 2025.New API Facility: Sigachi Orvakal Node
The new site spans over 25 acres in the Guttapadu-Orvakal industrial corridor. It is designed to offer high-volume manufacturing with flexible regulatory alignment for both regulated and semi-regulated markets. The facility is positioned to enhance Sigachi’s R&D responsiveness, speed up commercialisation timelines, and cater to new therapeutic segments.
According to Mr. Amit Raj Sinha, Managing Director and CEO, “FY25 has been a transformative year. With Orvakal, we add depth to our infrastructure and scale to our ambition. This facility gives us room to serve new therapeutic spaces and increase our responsiveness to global demand.”MCC: Sigachi’s Flagship Segment
Sigachi continues to lead the global excipient space with over 22,000 MTPA of MCC capacity, operating at over 80 percent utilisation. The company has developed more than 60 MCC grades under proprietary formulations, including its DAPOBAL process and acid recovery systems. MCC remains a key ingredient in oral solid dosage forms, and Sigachi’s offerings are widely used by both generics and innovators worldwide.
Its facilities hold certifications from USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and ISO 45001.Financial Highlights
In FY25, Sigachi reported revenue of ₹5,003 million, reflecting 25.4 percent growth, with EBITDA up 46.2 percent. The company has maintained strong operating margins and low debt, with 28 percent PAT CAGR over five years.
Innovation and Pipeline
Sigachi operates two DSIR-certified R&D centers in Hyderabad and Dahej. Its current roadmap includes:- Introduction of Croscarmellose Sodium (CCS)
- Expansion of co-processed MCC variants
- Entry into 3D-printed pharmaceutical applications
- Launch of an API-focused R&D and analytics hub by FY26
The company is also expanding into LATAM, ASEAN, and Middle East markets. Operations and maintenance (O&M) contracts now contribute 10 percent of group revenue. Over 98 percent of vendors meet ESG benchmarks.
At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.
- Introduction of Croscarmellose Sodium (CCS)